肺腺癌咨询

想帮国内亲戚问一下。亲戚在2021年9月因肺结节手术住院。病理示肺腺癌，非小细胞肺癌。基因检测示，KRAS2外显子突变。突变4.04%。目前国内还没有针对外显子2突变的针对性的靶向药。医生说，国外有，但价格是天价。目前，亲戚术后恢复良好，还远远不到需要吃靶向药的地步。但很想了解一下，如果真有这个药，药名是什么，规格和价钱又是怎么样的？亲戚作为一个非常特殊的个案病例，特殊就特殊在外显子2的突变上，如果现在需要口服药来维持，会出现目前国内无药可用的尴尬的现实。附上病理报告。谢谢大家。

Right now, whether or not a lung cancer patient has a KRAS mutation doesn’t change initial treatment decision making. Standard first-line therapy for a patient with KRAS positive lung cancer may be surgery, radiation, chemotherapy, immunotherapy or a combination based on the stage of their cancer. There is now a targeted therapy pill (also called a KRAS inhibitor) for patients with KRAS G12C. If a patient’s cancer stops responding to chemotherapy or immunotherapy (or a combination), they may be able to go on a targeted therapy pill called sotorasib. From https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/kras

Adagrasib, sotorasib都是kras g12c inhibitor。但是kras exon2不一定就是g12c mutation。其他kras mutation inhibitor还没有上市。kras exon2 mutation是KRAS mutation里最常见的,KRAS又是lung cancer里最常见的。